Lilach Cherry
Impact in
-
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
Papers in
-
- SARS-CoV-2 and COVID-19 Research 7
- SARS-CoV-2 detection and testing 2
-
- Protein purification and stability 4
- Viral Infectious Diseases and Gene Expression in Insects 2
- Co-authors
- Edith Lupu (6 shared papers)Sharon Melamed (4 shared papers)Noam Erez (4 shared papers)Tomer Israely (4 shared papers)Hagit Achdout (4 shared papers)Einat B. Vitner (3 shared papers)Boaz Politi (4 shared papers)Hadas Tamir (4 shared papers)
- Journals
- Vaccines (2 papers)Biotechnology and Bioengineering (1 paper)Journal of Biological Chemistry (1 paper)Nature Communications (1 paper)Materials (1 paper)
- Partner nations
- IsraelIndiaUnited States
In The Last Decade
Lilach Cherry
12 papers receiving 162 citations
Peers
Comparison fields: 5 of 56
- Infectious Diseases 65
- Virology 11
- Modeling and Simulation 10
- Epidemiology 53
- Molecular Biology 55
Countries citing papers authored by Lilach Cherry
This map shows the geographic impact of Lilach Cherry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilach Cherry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilach Cherry more than expected).
Fields of papers citing papers by Lilach Cherry
This network shows the impact of papers produced by Lilach Cherry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilach Cherry. The network helps show where Lilach Cherry may publish in the future.
Co-authors
The 25 scholars most cited alongside Lilach Cherry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 50 | |
| 2 | 2021 | 35 | |
| 3 | 2021 | 29 | |
| 4 | 2021 | 15 | |
| 5 | 2022 | 7 | |
| 6 | 2023 | 7 | |
| 7 | 2022 | 5 | |
| 8 | 2019 | 5 | |
| 9 | 2021 | 4 | |
| 10 | 2022 | 3 | |
| 11 | 2022 | 2 | |
| 12 | 2024 | 1 |
About Lilach Cherry
Lilach Cherry is a scholar working on Infectious Diseases, Molecular Biology, Epidemiology, Virology and Biomedical Engineering, having authored 12 papers that have together received 163 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (7 papers), Protein purification and stability (4 papers), Poxvirus research and outbreaks (2 papers), Herpesvirus Infections and Treatments (2 papers), SARS-CoV-2 detection and testing (2 papers), Viral Infectious Diseases and Gene Expression in Insects (2 papers), Nanoplatforms for cancer theranostics (1 paper) and Graphene and Nanomaterials Applications (1 paper). The work is most often cited by research in Infectious Diseases (65 citations), Virology (11 citations), Modeling and Simulation (10 citations), Epidemiology (53 citations) and Molecular Biology (55 citations). Lilach Cherry has collaborated with scholars based in Israel, India and United States. Frequent co-authors include Edith Lupu, Sharon Melamed, Noam Erez, Tomer Israely, Hagit Achdout, Einat B. Vitner, Boaz Politi, Hadas Tamir, Yfat Yahalom-Ronen and Nir Paran. Their work appears in journals such as Vaccines, Biotechnology and Bioengineering, Journal of Biological Chemistry, Nature Communications and Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.